 Braxia Scientific Corp has reported a near 50 increase in revenue in its fiscal year to end-March 2022 as it looks to significantly scale its offerings across North America. The medical research company, which provides ketamine treatments for depression and related disorders, said revenue came in at C1.49 million for fiscal 2022 compared to revenue of C1.008 million in the year to March 31, 2021, an increase of 47.5 year-on-year. 